

# A randomised trial of high dose therapy and autologous bone marrow transplantation versus continuing conventional combination chemotherapy for adults with lymphoblastic lymphoma

<b>Submission date</b> 01/07/2001	<b>Recruitment status</b> No longer recruiting	<input type="checkbox"/> Prospectively registered
		<input type="checkbox"/> Protocol
<b>Registration date</b> 01/07/2001	<b>Overall study status</b> Completed	<input type="checkbox"/> Statistical analysis plan
		<input checked="" type="checkbox"/> Results
<b>Last Edited</b> 28/11/2019	<b>Condition category</b> Cancer	<input type="checkbox"/> Individual participant data

**Plain English summary of protocol**  
Not provided at time of registration

## Contact information

**Type(s)**  
Scientific

**Contact name**  
Mr - -

**Contact details**  
UKCCCR Register Co-ordinator  
MRC Clinical Trials Unit  
222 Euston Road  
London  
United Kingdom  
NW1 2DA

## Additional identifiers

**Protocol serial number**  
LY01

## Study information

**Scientific Title**

A randomised trial of high dose therapy and autologous bone marrow transplantation versus continuing conventional combination chemotherapy for adults with lymphoblastic lymphoma

**Study objectives**

Not provided at time of registration

**Ethics approval required**

Old ethics approval format

**Ethics approval(s)**

Not provided at time of registration

**Study design**

Randomised controlled trial

**Primary study design**

Interventional

**Study type(s)**

Treatment

**Health condition(s) or problem(s) studied**

Lymphoma (non-Hodgkin's) cancer

**Interventions**

All patients receive induction therapy and conventional chemotherapy regimens. Patients achieving complete remission or partial remission are randomised to either:

1. Regimen A: Continue therapy on conventional regimen. The recommended conventional regimen is modified LSA2L2.
2. Regimen B: High dose therapy and ABMT.

**Intervention Type**

Drug

**Phase**

Not Applicable

**Primary outcome(s)**

Not provided at time of registration

**Key secondary outcome(s)**

Not provided at time of registration

**Completion date**

30/04/1997

**Eligibility****Key inclusion criteria**

1. Histologically documented lymphoblastic lymphoma
2. No prior chemotherapy or radiotherapy, except chemotherapy given for immediate relief of symptoms at presentation
3. Age 15 or over
4. All stages
5. No circulating blasts
6. Normal values for renal and hepatic function, unless directly attributable to lymphoma
7. Normal cardiac function
8. No evidence of Human Immunodeficiency Virus (HIV) infection

**Participant type(s)**

Patient

**Healthy volunteers allowed**

No

**Age group**

Adult

**Sex**

All

**Total final enrolment**

119

**Key exclusion criteria**

Patients will be excluded if they have HLA-identical siblings who are undergoing allogenic bone marrow transplantation. These patients should be registered with the trials office but will not be randomised.

**Date of first enrolment**

01/01/1992

**Date of final enrolment**

30/04/1997

**Locations****Countries of recruitment**

United Kingdom

England

**Study participating centre**

**MRC Clinical Trials Unit**

London

United Kingdom

NW1 2DA

# Sponsor information

## Organisation

Cancer Research UK (CRUK) (UK)

## ROR

<https://ror.org/054225q67>

# Funder(s)

## Funder type

Charity

## Funder Name

Cancer Research UK

## Alternative Name(s)

CR\_UK, Cancer Research UK - London, Cancer Research UK (CRUK), CRUK

## Funding Body Type

Private sector organisation

## Funding Body Subtype

Other non-profit organizations

## Location

United Kingdom

# Results and Publications

## Individual participant data (IPD) sharing plan

### IPD sharing plan summary

#### Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<a href="#">Results article</a>	results	01/06/2001	28/11/2019	Yes	No